See more : WiSA Technologies, Inc. (WISA) Income Statement Analysis – Financial Results
Complete financial analysis of Talis Biomedical Corporation (TLIS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Talis Biomedical Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Encavis AG (ENCVF) Income Statement Analysis – Financial Results
- NSD Co., Ltd. (9759.T) Income Statement Analysis – Financial Results
- Enterprise Bancorp, Inc. (EBTC) Income Statement Analysis – Financial Results
- Li Ning Company Limited (2331.HK) Income Statement Analysis – Financial Results
- Grupo SBF S.A. (SBFG3.SA) Income Statement Analysis – Financial Results
Talis Biomedical Corporation (TLIS)
About Talis Biomedical Corporation
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 412.00K | 3.65M | 0.00 | 10.94M | 3.98M | 2.39M |
| Cost of Revenue | 41.00K | 8.39M | 2.62M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 371.00K | -4.74M | -2.62M | 10.94M | 3.98M | 2.39M |
| Gross Profit Ratio | 90.05% | -129.76% | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 40.69M | 70.83M | 157.59M | 89.02M | 23.81M | 18.39M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 13.10M | 6.86M | 5.43M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.21M | 40.73M | 42.42M | 13.10M | 6.86M | 5.43M |
| Other Expenses | -1.72M | -1.16M | -8.19M | -10.94M | -3.98M | 0.00 |
| Operating Expenses | 67.19M | 110.40M | 191.82M | 91.18M | 26.70M | 21.43M |
| Cost & Expenses | 67.23M | 118.79M | 191.82M | 91.18M | 26.70M | 21.43M |
| Interest Income | 0.00 | 0.00 | 0.00 | 54.00K | 42.00K | 93.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 770.00K | 11.60M | 2.62M | 1.37M | 726.00K | 647.00K |
| EBITDA | -66.05M | -106.31M | -191.82M | -90.42M | -25.97M | -20.78M |
| EBITDA Ratio | -16,030.34% | -3,152.77% | 0.00% | -826.67% | -653.08% | -869.58% |
| Operating Income | -66.82M | -115.14M | -191.82M | -91.18M | -26.70M | -21.43M |
| Operating Income Ratio | -16,217.23% | -3,152.77% | 0.00% | -833.64% | -671.34% | -896.65% |
| Total Other Income/Expenses | 4.81M | 2.13M | -220.00K | 54.00K | -775.00K | 93.00K |
| Income Before Tax | -62.01M | -113.01M | -192.04M | -91.13M | -27.47M | -21.34M |
| Income Before Tax Ratio | -15,050.24% | -3,094.52% | 0.00% | -833.15% | -690.82% | -892.76% |
| Income Tax Expense | 0.00 | -2.13M | -1.58M | -54.00K | -42.00K | 93.00K |
| Net Income | -62.01M | -110.89M | -190.46M | -91.08M | -27.43M | -21.34M |
| Net Income Ratio | -15,050.24% | -3,036.28% | 0.00% | -832.66% | -689.77% | -892.76% |
| EPS | -34.12 | -62.45 | -126.13 | -314.06 | -182.88 | -141.85 |
| EPS Diluted | -34.12 | -62.45 | -126.13 | -314.06 | -182.88 | -141.85 |
| Weighted Avg Shares Out | 1.82M | 1.78M | 1.51M | 290.00K | 150.00K | 150.42K |
| Weighted Avg Shares Out (Dil) | 1.82M | 1.78M | 1.51M | 290.00K | 150.00K | 150.42K |
Why Is Talis Biomedical (TLIS) Stock Down 52% Today?
Talis Biomedical (NASDAQ: TLIS ) stock is falling on Wednesday after the company provided investors with an update on its restructuring plans. Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have...
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point...
7 Small-Cap Stocks to Sell in August Before They Crash and Burn
Although speculative enterprises tend to draw in a loyal band of followers, certain circumstances call for decisive action, as these small-cap stocks to avoid in August confirms. Nobody wants to be the guy or gal throwing in the towel.
Talis Biomedical Corporation (TLIS) Q2 2023 Earnings Call Transcript
Talis Biomedical Corporation (NASDAQ:TLIS ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Becky Markovich - Interim Chief...
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point...
Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point...
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point...
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point...
Talis Biomedical Corporation (TLIS) Q1 2023 Earnings Call Transcript
Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Becky Markovich - Interim Chief...
Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point...
Source: https://incomestatements.info
Category: Stock Reports